Amy Hicks, PhD
About Amy Hicks, PhD
Amy Hicks, PhD, serves as Principal Scientist at Entrada Therapeutics, where she leads projects related to in vivo models for various diseases. With a strong background in cellular and molecular biology, she has held significant roles at several research institutions and has contributed to key developments in her field.
Work at Entrada Therapeutics
Amy Hicks serves as a Principal Scientist at Entrada Therapeutics since 2021. In this role, she leads projects that involve collaboration with various stakeholders, including legal departments and contract research organizations (CROs), to develop in vivo models for diseases such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). Hicks has established Entrada's controlled substance program and manages one direct report. She has also implemented in-house in vivo functional testing and contributed to the design of a new vivarium space at the company.
Previous Experience at Korro Bio, Inc.
Prior to her current position, Amy Hicks worked as a Senior Scientist at Korro Bio, Inc. from 2019 to 2021 in Cambridge, Massachusetts. During her tenure, she focused on advancing scientific research and development initiatives within the organization. Her experience at Korro Bio contributed to her expertise in the field of molecular biology and therapeutic development.
Education and Expertise
Amy Hicks holds a Doctor of Philosophy (PhD) in Molecular Medicine and Translational Sciences from Wake Forest University Graduate School, which she completed from 2007 to 2012. She also earned two Bachelor of Science degrees in Cell/Cellular and Molecular Biology and Biochemistry from the University of Maine, where she studied from 2000 to 2005. Hicks's educational background provides her with a strong foundation in biological sciences, which is crucial for her work in drug development and research.
Research and Contributions
Throughout her career, Amy Hicks has made significant contributions to scientific research. She generated in vivo data that was included in Entrada Therapeutics' successful IPO filing package in October 2021. Additionally, she presented her research findings at the Muscular Dystrophy Association (MDA) conference in 2022. Hicks also performs target identification and validation by conducting literature searches and engaging with key opinion leaders, showcasing her commitment to advancing therapeutic strategies.
Previous Roles and Teaching Experience
Before her current role, Amy Hicks held several positions in academia and research. She was a Postdoctoral Research Associate at The Jackson Laboratory from 2013 to 2019 and served as an Adjunct Instructor at the College of the Atlantic in 2016 and 2018. Earlier in her career, she worked as a Research Associate I at Penn State University and as a Graduate Research Fellow at the Wake Forest Institute for Regenerative Medicine. These roles have enriched her experience and expertise in the field.